OC-0250: Technical and clinical experience with the 1st single room proton therapy system  by Klein, E. et al.
S126                                                                                                                                         3rd ESTRO Forum 2015 
 
composed to vary dose rate, MLC positions, jaw and gantry 
speed to push dynamic parameters to the limit.  
Planned vs. actual leaf positions, jaws and gantry were 
quantified by analyzing the linac's log files. A delivery 
robustness index was introduced by means of the ratio of the 
planned MLC path versus the actual MLC path. Delivery 
efficiency in terms of dose rate stability and delivery time 
was investigated for each of the 18 linacs.  
Dosimetric verification was performed at 3 institutes using 
the OCTAVIUS 4D system and Verisoft 6.0 (PTW) to examine 
intra-linac consistency. Relative dose differences were 
assessed by mean gamma (1mm/1%) for each control point 
and compared to the results of the log file evaluation. 
Results: Fourteen linacs delivered the benchmark plan 
without difficulty, while 4 linacs failed due to delivery 
termination. The linac inhibits were mostly related to dose 
rate and beam steering servo dysfunctions in rotational 
mode. Other inhibits were caused by tolerances that were set 
too tight. 
The mean leaf error during plan delivery was 0.28±0.15mm 
for all linacs. The maximum errors for MLC and jaw positions 
were found at control points where the moving direction 
reversed, where deviations up to 7.4mm were detected. 
Delivery robustness varied from 0.83 to 1.01, indicating the 
extent of MLC repositioning and overtravel. This index was 
found to correlate well with delivery time (R²=0.95), which 
varied from 80s to 128s, depending on the linac's ability to 
keep a constant low dose rate for arc segments demanding 
maximum leaf speed.  
Dosimetric evaluation of delivery robustness for plans 
including all control points resulted in a mean gamma of 
0.68±0.19, indicating very accurate plan reproducibility. 
Control point resolved analysis correlated very well with log 
file analysis, 3D gamma value display (fig.1) also reveals 
information about the error of mapped MLC leaf pair 
numbers. 
 
Conclusions: The test plan and procedure was found to be a 
valuable VMAT benchmark test to identify linac related 
malfunctions in dynamic mode. Delivery robustness was found 
to be related to dose rate stability and MLC overtravel. 
Overall, MLC errors were comparable even though delivery 
time and robustness varied considerably. The dosimetric 
evaluation provides strong evidence that log file indicated 
errors correlate with delivery accuracy for small arc 
segments. Log files contain valuable data to be used for 
acceptance testing of rotational techniques and proactive 
linac QA. 
   
OC-0250   
Technical and clinical experience with the 1st single room 
proton therapy system 
E. Klein1, T. Zhou1, J. Bradley1 
1Washington University Medical Center, Radiation Oncology, 
St. Louis, USA  
 
Purpose/Objective: On December 18, 2013 we treated our 
first patient with the single room Mevion S250 Proton Therapy 
System. This followed seven months of acceptance testing 
and commissioning, including; dosimetric data acquisition, 
safety checks, establishing quality assurance programs, 
mechanical and imaging checks, beam modeling validation, 
etc. 
Materials and Methods: The Mevion S250 possesses a 
compact synchro-cyclotron attached to a gantry due to its 
small size (1.8m diameter) and light weight (22 tons). The 
delivery system works in combination with a 6D robotic couch 
for allowing beam trajectories of any given beam angle. The 
system currently customizes beams using passive scattering 
and provides 3D-2D imaging via fixed x-rays, with a portable 
CT forthcoming for volumetric matching. Our treatment 
planning system is Varian Eclipse, V11, for which beam 
modeling and validation comprised the most of the 
commissioning time. The electronic medical record system is 
Elekta’s MOSIAQ 2.5, which provides connectivity to the 
Mevion System, for setup, imaging and treatment. 
Results: The treatment planning modeling and validation met 
a set gamma index of 1%, 1mm for 98% or more of points 
sampled. The image system quality was tested to be equal or 
better than current onboard imaging systems in our clinic. 
The neutron dose was measured to be < 1.0 mSv)/Gy for most 
clinical fields tested, alleviating concerns for pediatric 
treatments. The measured isocentricity of the gantry and 
couch was measured to be 0.5 and 0.6mm, respectively. The 
QA program developed includes a 30 minute procedure; 
including checks for; couch isocentricity, interlocks, warning 
indicators, imaging, and most importantly, dosimetric checks 
for three of 24 options. Daily, we measure output, 
modulation flatness, range, field symmetry, and distal 
falloff, all with a single exposure per option. In terms of 
machine operation and reliability, the uptime for the 
majority of treatment months was at least 95%. Clinical start 
up over the first 11 months included a variety of the first 100 
cases, predominantly; adult CNS, pediatrics, including Cranial 
Spinal (CS), lung, pelvis, liver, and H&N. Thorax patients 
receive weekly scans to ascertain if new adaptive plans are 
needed. We are currently treating 18-22 patients per day, 
with the caseload depending on the number of anesthesia 
and CSI cases. Currently all adult patients are being planned 
with a backup treatment plan for IMRT or conventional 
therapy. This is performed in order to; make proper and 
honest planning comparisons, as a backup plan in case the 
proton machine has significant downtime, and for billing 
justification purposes. 
Conclusions: The Mevion S250 has added a vital delivery 
option to compliment other treatment machines within our 
National Cancer Institute (USA) Comprehensive Cancer 
Center. 
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Purpose/Objective: Ion beams due to superior dose profile 
over photons and electrons may provide higher dose-
conformity and healthy tissue sparing. But due to high costs 
and huge size ion beam therapy is limited to a few centers 
only. A novel ion acceleration process via ultra-intense laser-
matter interaction, promises size and cost reduction. 
However, laser-driven beams are characterized by intense 
particle bunches with peak dose rates exceeding 
conventional values by several orders of magnitude, low 
repetition rate, broad energy spread and large divergence, 
thus are diverse from conventional beams. This requires new 
solutions for developing Laser-based Ion Beam Therapy (LIBT) 
for clinical application. The presented work is a result of an 
ongoing joint translational research project of several 
institutions aiming to establish LIBT with protons and shows 
the status in five main challenges. 
Materials and Methods: I) Laser-based technology has been 
established, with protons (upto 20 MeV) via 150 TW laser 
system, for systematic radiobiological studies with human 
cell-lines and small animals with fixed beamline. 
II) For translation towards patient irradiation, increase of 
proton energy from 20 to 230 MeV by increasing the laser 
power from 150 TW to ~1 PW is required and in progress. 
III) Furthermore, a compact ion beam gantry system is 
designed based on pulsed magnets (PM), with integrated 
laser-particle acceleration chamber, novel beam capturing 
and energy selection system. A new pulsed scanning system 
for wide beams with broad energies is designed for 
irradiations with clinical accuracy. 
IV) The light-weight iron-less high-field PMs are being 
developed for gantry realization. These are non-trivial and 
extremely challenging to design.  
V) A new 3D TPS has been developed for new dose delivery 
and treatment planning strategies for LIBT.  
Results: No overall difference in the radiobiological 
effectiveness between laser-driven and conventional beams 
was detected to date. Therefore, a comparison of dose plans 
by treatment planning system is possible to evaluate the 
features of LIBT. The evaluation of treatment plans shows 
laser driven broad energetic beams are feasible for clinical 
application.  
Our double-achromatic 360° isocentric pulsed gantry design 
is ~2.5x smaller than conventional gantries (see fig.) and is 
capable of disperssionless scanning of high acceptance beams 
through 20x20 cm2 field size.  
For the realization, PMs have been designed and developed. 
A pulsed solenoid, for particle capturing and focusing, has 
been successfully tested at laser-driven beams. A novel 10 T 
compact pulsed 45° sector magnet has been developed and 
tested. Also, a pulsed high acceptance quadrupole with 250 
T/m gradient is being developed. 
 
 
 
Conclusions: LIBT is a promising compact alternative and 
could change IBT, yet requires substantial development 
towards clinical application.  
Supported by German BMBF, no. 03Z1N511 & DFG cluster of 
excellence MAP. 
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Purpose/Objective: Radiation treatment planning with a 
commercial TPS is a trial and error process that often leads 
to sub-optimal organ sparing. We developed a method to 
predict feasible target and organ at risk (OAR) dose levels 
prior to the start of the treatment planning process. These 
predictions can be used (i) to guide the treatment planner to 
achieve optimal OAR sparing or target dose escalation; (ii) for 
quality assurance of the treatment planning process; (iii) to 
identify patients that may benefit from adaptive RT; (iv) to 
